Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06313047
Status:
COMPLETED
Last Update Posted:
2024-03-28
First Post:
2024-03-09
Brief Title:
Pharmacogenetic of Doxorubicin in HCC
Sponsor:
Rehab Werida
Organization:
Damanhour University
Study Overview
Official Title:
Pharmacogenetic of Doxorubicin in Patients With Hepatocellular Carcinoma A Prospective Cohort Study
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study included 81 HCC patients both male and female Prior to being assessed for eligibility each recruited patient with HCC received a comprehensive review of their medical history physical status and laboratory results Every research participant take part in the experiment and provided written informed consent
Detailed Description:
All patients had their baseline viral indicators for HBV and HCV evaluated Additionally blood samples were taken for genotyping All patients underwent evaluations of their kidney liver and alpha fetoprotein AFP functions as well as their complete blood count CBC at both the baseline and follow-up appointments To evaluate the efficacy of TACE triple pelvic abdominal CT scans were performed both prior to and one month later Using triphasic pelviabdominal CT patients who achieved complete response CR were monitored for up to 13 months following chemotherapy in order to identify recurrence Follow-up appointments were planned to identify patients responces or any negative effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None